Clinical Trials
31 trialsBelinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
University of Miami
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
PTCL
Spectrum Pharmaceuticals, Inc
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Acrotech Biopharma Inc.
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Acrotech Biopharma Inc.
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Institutes of Health Clinical Center (CC)
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
National Cancer Institute (NCI)
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
PXD101 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Massachusetts General Hospital
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
National Institutes of Health Clinical Center (CC)
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Spectrum Pharmaceuticals, Inc
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Valerio Therapeutics
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Valerio Therapeutics
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Valerio Therapeutics
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)